(MDEV) First Trust - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • • Health
MDEV: Medical, Equipment, Devices, Supplies, Diagnostic, Implants, Instruments
The fund will invest at least 80% of its net assets in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies that are associated with the medical equipment industry, as determined by the index provider.
Additional Sources for MDEV ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MDEV ETF Overview
| Market Cap in USD | 3m |
| Category | Health |
| TER | 0.70% |
| IPO / Inception | 2021-06-22 |
MDEV ETF Ratings
| Growth 5y | -11.0% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -67.1 |
| Analysts | - |
| Fair Price Momentum | 19.85 USD |
| Fair Price DCF | - |
MDEV Dividends
No Dividends PaidMDEV Growth Ratios
| Growth Correlation 3m | -51.1% |
| Growth Correlation 12m | 47.3% |
| Growth Correlation 5y | -23.3% |
| CAGR 5y | -3.76% |
| CAGR/Mean DD 5y | -0.15 |
| Sharpe Ratio 12m | 0.41 |
| Alpha | -17.82 |
| Beta | 1.02 |
| Volatility | 13.03% |
| Current Volume | 0k |
| Average Volume 20d | 2.9k |
What is the price of MDEV stocks?
As of January 23, 2025, the stock is trading at USD 22.01 with a total of 42 shares traded.
Over the past week, the price has changed by +4.00%, over one month by +5.91%, over three months by +0.98% and over the past year by +8.89%.
As of January 23, 2025, the stock is trading at USD 22.01 with a total of 42 shares traded.
Over the past week, the price has changed by +4.00%, over one month by +5.91%, over three months by +0.98% and over the past year by +8.89%.
Is First Trust a good stock to buy?
Neither. Based on ValueRay Analyses, First Trust is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -11.02 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MDEV as of January 2025 is 19.85. This means that MDEV is currently overvalued and has a potential downside of -9.81%.
Neither. Based on ValueRay Analyses, First Trust is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -11.02 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MDEV as of January 2025 is 19.85. This means that MDEV is currently overvalued and has a potential downside of -9.81%.
Is MDEV a buy, sell or hold?
First Trust has no consensus analysts rating.
First Trust has no consensus analysts rating.
What are the forecast for MDEV stock price target?
According to ValueRays Forecast Model, MDEV First Trust will be worth about 22.1 in January 2026. The stock is currently trading at 22.01. This means that the stock has a potential upside of +0.32%.
According to ValueRays Forecast Model, MDEV First Trust will be worth about 22.1 in January 2026. The stock is currently trading at 22.01. This means that the stock has a potential upside of +0.32%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22.1 | 0.3% |